May 11, 2026
FOR IMMEDIATE RELEASE

Company name: Watahan & Co., Ltd.
Name of representative: Isamu Nohara, President & CEO
(Securities code:3119; Prime Market)
Inquiries: Ayako Banno, Director
(Telephone: +81-0265-25-8155)

To Whom It May Concern

Notice regarding recording of extraordinary loss

We hereby announce that we have recorded an extraordinary loss in our consolidated financial results for the fiscal year ending March 2026, as detailed below.

1. Occurrence of extraordinary losses (impairment losses) and their details

In the fiscal year ending March 2026, due to the occurrence of substandard products among some active pharmaceutical ingredients manufactured by our consolidated subsidiary, Watahan Trading Co., Ltd., we recorded an impairment loss of 758 million yen as an extraordinary loss related to those products.

2. Impact on consolidated financial results

This matter is reflected in the "Consolidated Financial Results for the Fiscal Year Ending March 2026 (Japanese GAAP)" published today.

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.